Axonal degeneration in the pathogenesis of multiple sclerosis

Journal of the Neurological Sciences

Volumn 170, Issue 1, 1999, Pages 11-18

  Silber, Eli ^a   Sharief, Mohammad K ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Axon; Multiple sclerosis

Indexed keywords

CYTOKINE; NITRIC OXIDE; PROTEINASE;

CYTOSKELETON; DEMYELINATION; DISABILITY; DISEASE COURSE; IMMUNOTHERAPY; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NERVE LESION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

AXONS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MULTIPLE SCLEROSIS; NERVE DEGENERATION;

EID: 0032716144     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(99)00178-1     Document Type: Review

References (97)

1. Ffrench-Constant C. Pathogenesis of multiple sclerosis. Lancet. 343:(8892):1994;271-275.
2. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain. 120:(Pt. 3):1997;393-399.
3. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mörk S., Bõ L. Axonal transection in the lesions of multiple sclerosis. New Engl J Med. 338:(5):1998;278-285.
4. Greenfield J., King L. Observations on the histopathology of the cerebral lesions in disseminated sclerosis. Brain. 59:1936;445-458.
5. Lassmann H., Suchanek G., Ozawa K. Histopathology and the blood-cerebrospinal fluid barrier in multiple sclerosis. Ann Neurol. 36:(Suppl.):1994;542-546.
6. Ozawa K., Suchanek G., Breitschopf H., Bruck W., Budka H., Jellinger K., et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain. 117:(Pt. 6):1994;1311-1322.
7. Gass A., Barker G.J., Kidd D., Thorpe J.W., MacManus D., Brennan A., et al. Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol. 36:(1):1994;62-67.
8. van Walderveen M.A.A., Barkhof F., Hommes O.R., Polman C.H., Tobi H., Frequin S.T., Valk J. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology. 45:(9):1995;1684-1690.
9. McDonald W.I. Rachelle Fishman-Matthew Moore Lecture. The pathological and clinical dynamics of multiple sclerosis. J Neuropathol Exp Neurol. 53:(4):1994;338-343.
10. Narayanan S., Fu L., Pioro E., De S.N., Collins D.L., Francis G.S., et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol. 41:(3):1997;385-391.
11. Losseff N.A., Webb S.L., O'Riordan J.I., Page R., Wang L., Barker G.J., et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain. 119:(Pt. 3):1996;701-708.
12. Davie C.A., Barker G.J., Webb S., Tofts P.S., Thompson A.J., Harding A.E., et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain. 118:(Pt. 6):1995;1583-1592.
13. Truyen L., van Waesberghe J.H.T.M., van Walderveen M.A.A., van Oosten B.W., Polman C.H., Hommes O.R., et al. Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 47:(6):1996;1469-1476.
14. Laferriere N.B., MacRae T.H., Brown D.L. Tubulin synthesis and assembly in differentiating neurons. Biochem Cell Biol. 75:(2):1997;103-117.
15. Fuchs E., Cleveland D.W. A structural scaffolding of intermediate filaments in health and disease. Science. 279:1998;514-519.
16. Lee M.K., Cleveland D.W. Neurofilament function and dysfunction: involvement in axonal growth and neuronal disease. Curr Opinion Cell Biol. 6:1996;34-40.
17. Ohara O., Gahara Y., Miyake T., Teraoka H., Kitamura T. Neurofilament deficiency in quail caused by nonsense mutation in neurofilament-L gene. J Cell Biol. 121:(2):1993;387-395.
18. Sakaguchi T., Okada M., Kitamura T., Kawasaki K. Reduced diameter and conduction velocity of myelinated fibers in the sciatic nerve of a neurofilament-deficient mutant quail. Neurosci Lett. 153:(1):1993;65-68.
19. Eyer J., Peterson A. Neurofilament-deficient axons and perikaryal aggregates in viable transgenic mice expressing a neurofilament-beta-galactosidase fusion protein. Neuron. 12:(2):1994;389-405.
20. de Waegh S.M., Lee V.M., Brady S.T. Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell. 68:(3):1992;451-463.
21. Hsieh S.T., Kidd G.J., Crawford T.O., Xu Z., Lin W.M., Trapp B.D., et al. Regional modulation of neurofilament organization by myelination in normal axons. J Neurosci. 14:(11 Pt. 1):1994;6392-6401.
22. Kirkpatrick L.L., Brady S.T. Modulation of the axonal microtubule cytoskeleton by myelinating Schwann cells. J Neurosci. 14:(12):1994;7440-7450.
23. Barnes D., Munro P.M., Youl B.D., Prineas J.W., McDonald W.I. The longstanding MS lesion. A quantitative MRI and electron microscopic study. Brain. 114:(Pt. 3):1991;1271-1280.
24. Prineas J.W., Connell F. The fine structure of chronically active multiple sclerosis plaques. Neurology. 28:(9 Pt. 2):1978;68-75.
25. Rodriguez M., Scheithauer B. Ultrastructure of multiple sclerosis. Ultrastruct Pathol. 18:(1-2):1994;3-13.
26. Mews I., Bergmann M., Bunkowski S., Gullotta F., Bruck W. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Multiple Sclerosis. 4:(2):1998;55-62.
27. Hardy J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20:(4):1997;154-159.
28. Sherriff F.E., Bridges L.R., Sivaloganathan S. Early detection of axonal injury after human head trauma using immunocytochemistry for beta-amyloid precursor protein. Acta Neuropathologica. 87:(1):1994;55-62.
29. Gehrmann J., Banati R.B., Cuzner M.L., Kreutzberg G.W., Newcombe J. Amyloid precursor protein (APP) expression in multiple sclerosis lesions. GLIA. 15:(2):1995;141-151.
30. Banati R.B., Gehrmann J., Lannes-Vieira J., Wekerle H., Kreutzberg G.W. Inflammatory reaction in experimental autoimmune encephalomyelitis (EAE) is accompanied by a microglial expression of the beta A4-amyloid precursor protein (APP). GLIA. 14:(3):1995;209-215.
31. Raine C.S., Cross A.H. Axonal dystrophy as a consequence of long-term demyelination. Laboratory Investigation. 60:(5):1989;714-725.
32. Miller D.H., Albert P.S., Barkhof F., Francis G., Frank J.A., Hodgkinson S., et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol. 39:1996;6-16.
33. Miller D.H., Grossman R.I., Reingold S.C., McFarland H.F. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain. 121:1998;3-24.
34. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 45(7):1995;1277-1285.
35. Kappos L., Moeri D., Radue E.W., Schoetzau A., Schweikert K., Barkhof F. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and change in disability or impairment in multiple sclerosis: a meta-analysis. Lancet. 353:1999;964-969.
36. Hiehle J.F.J., Grossman R.I., Ramer K.N., Gonzalez-Scarano F., Cohen J.A. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. Am J Neuroradiol. 16:(1):1995;69-77.
37. Loevner L.A., Grossman R.I., McGowan J.C., Ramer K.N., Cohen J.A., Barres B.A., et al. Characterization of multiple sclerosis plaques with T1-weighted MR and quantitative magnetization transfer. Am J Neuroradiol. 16:(7):1995;1473-1479.
38. vanWalderveen M.A.A., Scheltens P.H., vanWaesberghe J.H., Barkhof F., Ravid R., Valk J., et al. Hypointense lesions on T1-weighted SE MR images correlate with axonal loss in multiple sclerosis. J Neurol. S84:1997.
39. Kidd D., Thorpe J.W., Thompson A.J., Kendall B.E., Moseley I.F., MacManus D.G. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology. 43:(12):1993;2632-2637.
40. Losseff N.A., Wang L., Lai H.M., Yoo D.S., Gawne-Cain M.L., McDonald W.I. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain. 119:(Pt. 6):1996;2009-2019.
41. Arnold D.L., Riess G.T., Matthews P.M., Francis G.S., Collins D.L., Wolfson C., et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol. 36:(1):1994;76-82.
42. Fu L., Matthews P.M., De Stefano N., Worsley K.J., Narayanan S., Francis G.S., et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain. 121:(Pt. 1):1998;103-113.
43. van Waesberghe J.H., van Walderveen M.M., Castelijns J.A., Scheltens Ph., Lycklama Nijeholt G.J. Natural history of hypointense lesions in multiple sclerosis. J Neurol. 244:(Suppl. 3):1997;244.
44. Davie C.A., Hawkins C.P., Barker G.J., Brennan A., Tofts P.S., Miller D.H., et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 117:(Pt. 1):1994;49-58.
45. Barres B.A., Raff M.C., Canoll P.D., Musacchio J.M., Hardy R., Reynolds R. Proliferation of oligodendrocyte precursor cells depends on electrical activity in axons. Nature. 361:(6409):1993;258-260.
46. Barres B.A., Raff M.C., Gaese F., Bartke I., Dechant G., Barde Y.A. A crucial role for neurotrophin-3 in oligodendrocyte development. Nature. 367:(6461):1994;371-375.
47. Canoll P.D., Musacchio J.M., Hardy R., Reynolds R., Marchionni M.A., Salzer J.L. GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron. 17:(2):1996;229-243.
48. Meyer-Franke A., Kaplan M.R., Pfrieger F.W., Barres B.A. Characterization of the signalling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron. 15:(4):1995;805-819.
49. Fournier A.E., McKerracher L. Tubulin expression and axonal transport in injured and regenerating neurons in the adult mammalian central nervous system. Biochem Cell Biol. 73:(9-10):1995;659-664.
50. Schwab M.E., Caroni P. Oligodendrocytes and CNS myelin are nonpermissive substrates for neurite growth and fibroblast spreading in vitro. J Neurosci. 8:(7):1988;2381-2393.
51. Schnell L., Schwab M.E. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature. 343:(6255):1990;269-272.
52. Caroni P., Schwab M.E. Two membrane protein fractions from rat central myelin with inhibitory properties for neurite growth and fibroblast spreading. J Cell Biol. 106:(4):1988;1281-1288.
53. Compston A. Brain repair. J Int Med. 237:(2):1995;127-134.
54. Drulovic J., Mostarica-Stojkovic M., Levic Z., Stojsavljevic, Pravica V., Mesaros S. Interleukin-12 and tumor-necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients. J Neurol Sci. 147:(2):1997;145-150.
55. Sharief M., Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. New Engl J Med. 325:1991;467-472.
56. van der Laan J., Ruul S.R., Weber K.S., Lodder I.J., Dopp E.A., Dijkstra C.D. Macrophage phagocytosis of myelin in vitro determined by flow-cytometry-phagocytosis is mediated by CR3 and induces production of tumor-necrosis-factor-alpha and nitric-oxide. J Neuroimmunol. 70:(2):1996;145-152.
57. Selmaj K., Raine C.S., Farooq M., Norton W.T., Brosnan C.F. Cytokine cytotoxicity against oligodendrocytes. J Immunol. 147:1991;1522-1529.
58. 2+ and induces a depolarization in cultured astroglial cells. Brain. 119:(Pt. 6):1996;2021-2027.
59. Bo L., Dawson T.M., Wesselingh S. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol. 36:1994;778-786.
60. Giovannoni G., Heales S., Silver N., O'Riordan J.I., Miller R., Land J. Raised serum nitrate and nitrite levels in patients with multiple sclerosis. J Neurol Sci. 145:1997;77-81.
61. Johnson A., Land J., Thompson E.J., Bolanos J., Clark J., Heales S. Evidence for increased nitric oxide production in multiple sclerosis. J Neurol Neurosurg Psychiatry. 58:1995;107.
62. Boullerne A., Petry K., Meynard M., Geffard M. Indirect evidence for nitric oxide involvement in multiple sclerosis by characterization of circulating antibodies directed against conjugated S-nitrosocysteine. J Neuroimmunol. 60:(1-2):1995;117-124.
63. Brenner T., Brocke S., Szafer F., Sobel R.A., Parkinson J.F., Perez D.H., Steinman L. Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J Immunol. 158:(6):1997;2940-2946.
64. Cross A.H., Misko T., Lin R., Hickey W., Trotter J., Tilton R. Aminoguanadine, an inhibitor of inducible nitric-oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest. 93:1994;2684-2690.
65. Hooper D.C., Bagstra O., Marini J.C., Zborek A., Ohnishi S.T., Kean R., et al. Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for treatment of multiple sclerosis. Proc Natl Acad Sci USA. 94:1997;2528-2533.
66. Chou S.M., Wang H.S., Taniguchi A. Role of SOD-1 and nitric oxide/cyclic GMP cascade on neurofilament aggregation in ALS/MND. J Neurol Sci. 139:(Suppl.):1996;16-26.
67. Redford E., Kapoor R., Smith K.J. Nitric oxide donors selectively block axonal conduction: demyelinated axons are especially susceptible. Brain. 120:1997;2149-2157.
68. Smith K, Kapoor R, Hall SM et al. Nitric oxide donors cause persistant axonal damage: Electrically active axons are especially susceptible [Abstract]. Society for Neuroscience, 28th Annual Meeting (Abstract 737.2) 1998.
69. Garren H., Steinman L., Lock C. The specificity of the antibody response in multiple sclerosis. Ann Neurol. 43:(1):1998;4-6.
70. Zeman A.Z., Kidd D., McLean B.N., Kelly M.A., Francis D.A., Miller D.H., et al. A study of oligoclonal band negative multiple sclerosis. J Neurol Neurosurg Psychiatry. 60:(1):1996;27-30.
71. Sellebjerg F.T., Frederiksen J.L., Olsson T. Anti-myelin basic protein and anti-proteolipid protein antibody-secreting cells in the cerebrospinal fluid of patients with acute optic neuritis. Archiv Neurol. 51:(10):1994;1032-1036.
72. Gerritse K., Deen C., Fasbender M., Ravid R., Boersma W., Claassen E. The involvement of specific antimyelin basic protein antibody-forming cells in multiple sclerosis immunopathology. J Neuroimmunol. 49:(1-2):1994;153-159.
73. Genain C.P., Nguyen M.H., Letvin N.L., Pearl R., Davis R.L., Adelman M., et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest. 96:(6):1995;2966-2974.
74. Linington C., Bradl M., Lassmann H., Brunner C., Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol. 130:(3):1988;443-454.
75. Genain C.P., Canella B., Hauser S.L., Raine C.S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nature Med. 5:(2):1999;170-175.
76. Prabhakar S., Kurien E., Gupta R.S., Zielinski S., Freedman M.S. Heat shock protein immunoreactivity in CSF: correlation with oligoclonal banding and demyelinating disease. Neurology. 44:(9):1994;1644-1648.
77. Kojima K., Berger T., Lassmann H., Hinze-Selch D., Zhang Y., Gehrmann J., et al. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia. J Exp Med. 180:(3):1994;817-829.
78. Kaiser R. Intrathecal immune response in patients with neuroborreliosis: specificity of antibodies for neuronal proteins. J Neurol. 242:(5):1995;319-325.
79. Darnell R.B. Onconeural antigens and the paraneoplastic neurological disorders: At the intersection of cancer, immunity and the brain. Proc Natl Acad Sci USA. 93:1996;4529-4536.
80. Brady S.T. Motor neurons and neurofilaments in sickness and health. Cell. 73:1993;1-3.
81. Rosengren L.E., Karlsson J.E., Persson L.I., Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament proteins in CSF. J Neurochem. 67:(5):1996;2013-2018.
82. Bahmanyar S., Gajdusek D.C., Sotelo J., Gibbs C.J. Jr., Toh B.H., Gibbs C.J.J., et al. Longitudinal spinal cord sections as substratum for anti-neurofilament antibody detection. J Neurol Sci. 53:(1):1982;85-90.
83. Toh B.H., Gibbs C.J.J., Gajdusek D.C., Tuthill D.D., Dahl D. The 200- and 150-kDa neurofilament proteins react with IgG autoantibodies from chimpanzees with kuru or Creutzfeldt-Jakob disease; a 62-kDa neurofilament-associated protein reacts with sera from sheep with natural scrapie. Proc Nat Acad Sci USA. 82:(11):1985;3894-3896.
84. Couratier P., Yi F.-H., Preud'homme J.-L., Clavelou P., White A., Sindou P., et al. Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. J Neurol Sci. 154:1998;137-145.
85. Nemni R., Feltri M.L., Fazio R., Quattrini A., Lorenzetti I., Corbo M., Canal N. Axonal neuropathy with a monoclonal IgG kappa that binds to a neurofilament protein. Ann Neurol. 28:1990;361-364.
86. Nobile-Orazio E., Manfredini E., Carpo M., Meucci N., Monaco S., Ferrari, Bonetti B., et al. Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol. 36:(3):1994;416-424.
87. Stefansson K., Marton L.S., Dieperink M.E., Molnar G.K., Schlaepfer W.W., Helgason C.M. Circulating autoantibodies to the 200 000-dalton protein of neurofilaments in the serum of healthy individuals. Science. 228:(4703):1985;1117-1119.
88. Newcombe J., Gahan S., Cuzner M.L., Connolly A.M., Pestronk A., Trotter J.L., et al. Serum antibodies against central nervous system proteins in human demyelinating disease. Clin Exper Immunol. 59:(2):1985;383-390.
89. Lycke J.N., Karlsson J.E., Rosengren L.E. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol, Neurosurg Psychiatry. 64:1998;402-404.
90. Connolly A.M., Pestronk A., Trotter J.L., Feldman E.L., Cornblath D.R., Olney R.K. High-titer selective serum anti-beta-tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. Neurology. 43:(3 Pt. 1):1993;557-562.
91. Blancher A., Oksman F., Lymberi P., Calvas P., Cambon-Thomsen A., Clanet M. Human monoclonal autoantibodies produced by hybridomas derived from lymphocytes of multiple sclerosis patients. Res Immunol. 140:(7):1989;711-724.
92. Screpanti I., Meco D., Scarpa S., Morrone S., Frati L., Gulino A. Neuromodulatory loop mediated by nerve growth factor and interleukin 6 in thymic stromal cell cultures. Proc Natl Acad Sci USA. 89:(8):1992;3209-3212.
93. Vesanen M., Wessman M., Salminen M., Vaheri A. Activation of integrated human immunodeficiency virus type I in human neuroblastoma cells by the cytokines tumour necrosis factor alpha and interleukin-6. J Gen Virol. 73:(Pt. 7):1992;1753-1760.
94. Orlino E.N., Olmstead C.E., Lazareff J.A., Peacock W.J., Fisher R.S., Fluharty A.L. An enzyme immunoassay for neuron-specific enolase in cerebrospinal fluid. Biochem Molec Med. 61:1997;41-46.
95. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 39:(3):1996;285-294.
96. Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet. 352:(9139):1998;1498-1504.
97. Placebo-controlled multicentre randomised trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet. 352:(9139):1998;1491-1497.